NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

6261. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

6262. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report

6263. Tezepelumab for severe asthma: final report

6264. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report

6265. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report

6266. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

6267. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report

6268. Health care affordability improved between 2019 and 2022 under pandemic health coverage policies: findings from the Well-Being and Basic Needs Survey